Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a 0,1,6 Mth Schedule in Healthy Female Subjects Aged 10-14 Yrs
Study participants will receive either HPV or hepatitis A vaccine, study duration will last
for 7 months and involve a total of 4 visits.
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
To evaluate antibody responses against HPV-16 and HPV-18 in all HPV vaccine recipients at Month 7.
GSK Clinical Trials
Korea: Food and Drug Administration